We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accenture Brings Open Partner Ecosystem for Drug Discovery
Read MoreHide Full Article
Accenture plc (ACN - Free Report) has modeled an open partner ecosystem, aimed at helping independent software vendors (ISVs) and life sciences companies collaborate to speed up and enhance drug discovery.
The ecosystem is an integral part of the cloud-based informatics research platform, which is being developed by Accenture in collaboration with Merck (MRK - Free Report) on Amazon’s (AMZN - Free Report) Amazon Web Services (“AWS”). The platform enables scientific research-based organizations in the life sciences industry to quickly access, aggregate and analyze research data from multiple applications. It facilitates easier collaboration across the R&D enterprise, including external partners.
The new ecosystem will enable ISVs leverage the platform’s use of open, industry-standard-based application programming interfaces (APIs) to integrate technology components, applications and content into the platform.
As a result, life sciences companies will be able to provide researchers access to innovative capabilities such as small-molecule and biological-entity registration, biological assay data capture, genomics data analysis, image storage and analysis and artificial intelligence.
In the past year, shares of Accenture have gained 7% compared with the 1.7% rise of the Zacks S&P 500 composite.
To Conclude
We believe that the latest move will help Accenture boost its Products segment as it comprises the Life Sciences industry group, which serves pharmaceutical, medical technology and biotechnology companies. Performance of this segment was particularly strong in the last reported quarter, with revenues increasing 12% on a year-over-year basis.
A better-ranked stock in the broader Zacks Business Services sector is WEX Inc. (WEX - Free Report) , carrying a Zacks Rank #2 (Buy). The long-term expected EPS (three to five years) growth rates for WEX is 15%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Accenture Brings Open Partner Ecosystem for Drug Discovery
Accenture plc (ACN - Free Report) has modeled an open partner ecosystem, aimed at helping independent software vendors (ISVs) and life sciences companies collaborate to speed up and enhance drug discovery.
The ecosystem is an integral part of the cloud-based informatics research platform, which is being developed by Accenture in collaboration with Merck (MRK - Free Report) on Amazon’s (AMZN - Free Report) Amazon Web Services (“AWS”). The platform enables scientific research-based organizations in the life sciences industry to quickly access, aggregate and analyze research data from multiple applications. It facilitates easier collaboration across the R&D enterprise, including external partners.
The new ecosystem will enable ISVs leverage the platform’s use of open, industry-standard-based application programming interfaces (APIs) to integrate technology components, applications and content into the platform.
As a result, life sciences companies will be able to provide researchers access to innovative capabilities such as small-molecule and biological-entity registration, biological assay data capture, genomics data analysis, image storage and analysis and artificial intelligence.
In the past year, shares of Accenture have gained 7% compared with the 1.7% rise of the Zacks S&P 500 composite.
To Conclude
We believe that the latest move will help Accenture boost its Products segment as it comprises the Life Sciences industry group, which serves pharmaceutical, medical technology and biotechnology companies. Performance of this segment was particularly strong in the last reported quarter, with revenues increasing 12% on a year-over-year basis.
Zacks Rank & Stocks to Consider
Accenture currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked stock in the broader Zacks Business Services sector is WEX Inc. (WEX - Free Report) , carrying a Zacks Rank #2 (Buy). The long-term expected EPS (three to five years) growth rates for WEX is 15%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>